| scholarly article | Q13442814 |
| P50 | author | Pamela J. Bjorkman | Q2048641 |
| Charles M. Rice | Q22669757 | ||
| Michel C. Nussenzweig | Q24804686 | ||
| Albert Ko | Q26706202 | ||
| Marina Caskey | Q54438095 | ||
| Daniel M Weinberger | Q56363858 | ||
| Thiago Yukio Kikuchi Oliveira | Q56490386 | ||
| Davide F. Robbiani | Q73336910 | ||
| Priscilla Christina Olsen | Q90239074 | ||
| Gielson Almeida Sacramento | Q91410002 | ||
| Margaret R MacDonald | Q91593460 | ||
| Lion F K Uhl | Q96174819 | ||
| Ricardo Khouri | Q30650237 | ||
| Nivison Nery | Q30650779 | ||
| Federico Costa | Q30650817 | ||
| Elsio A Wunder | Q40699846 | ||
| P2093 | author name string | Anthony P West | |
| Arlene Hurley | |||
| Mitermayer G Reis | |||
| Jennifer R Keeffe | |||
| Leonia Bozzacco | |||
| Anna Gazumyan | |||
| Lilian Nogueira | |||
| Roshni Patel | |||
| Gustavo Reyes-Teran | |||
| Jovana Golijanin | |||
| Santiago Avila-Rios | |||
| Dennis Schaefer-Babajew | |||
| Marianna Agudelo | |||
| Mohsan Saeed | |||
| Stephanie A Azzopardi | |||
| Thomas Eisenreich | |||
| Yu E Lee | |||
| Kai-Hui Yao | |||
| Antonio R P de Almeida | |||
| Cibele Orge | |||
| Edgar E Sevilla-Reyes | |||
| Harry B Gristick | |||
| Joy Pai | |||
| Neena M Thomas | |||
| P2860 | cites work | Zika Virus Infection in Pregnant Women in Rio de Janeiro — Preliminary Report | Q23005539 |
| The 3.8 Å resolution cryo-EM structure of Zika virus | Q23680595 | ||
| Phylogeny of Zika Virus in Western Hemisphere, 2015 | Q24047862 | ||
| Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody | Q24067948 | ||
| Structure of the thermally stable Zika virus | Q24082710 | ||
| Emergence of Congenital Zika Syndrome: Viewpoint From the Front Lines | Q24261097 | ||
| Zika virus: History, emergence, biology, and prospects for control | Q24261421 | ||
| Accuracy of Dengue Reporting by National Surveillance System, Brazil | Q24273377 | ||
| Present and future arboviral threats | Q24289450 | ||
| Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses | Q24649949 | ||
| PHENIX: a comprehensive Python-based system for macromolecular structure solution | Q24654617 | ||
| Antibody recognition of a highly conserved influenza virus epitope | Q24655932 | ||
| Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus | Q24737245 | ||
| Structural basis of potent Zika–dengue virus antibody cross-neutralization | Q24740325 | ||
| Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells | Q21562507 | ||
| Probable non-vector-borne transmission of Zika virus, Colorado, USA | Q22240615 | ||
| Outbreak of Exanthematous Illness Associated with Zika, Chikungunya, and Dengue Viruses, Salvador, Brazil | Q22330692 | ||
| Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation. | Q25138202 | ||
| Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus | Q25161212 | ||
| Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus | Q26247258 | ||
| Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection | Q26252507 | ||
| Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016 | Q26261632 | ||
| Immunogenic cross-talk between dengue and Zika viruses | Q26437328 | ||
| Assessing the global threat from Zika virus | Q27010603 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication | Q27472912 | ||
| Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein | Q27472922 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 | Q27663293 | ||
| Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 | ||
| Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 | ||
| The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution | Q27730234 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| Overview of the CCP4 suite and current developments | Q27860782 | ||
| iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM | Q27861099 | ||
| Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy | Q28005781 | ||
| Prolonged Detection of Zika Virus in Vaginal Secretions and Whole Blood | Q28114599 | ||
| Zika Virus Pathogenesis and Tissue Tropism | Q28733400 | ||
| The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis | Q28804225 | ||
| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity | Q29196526 | ||
| A structural perspective of the flavivirus life cycle | Q29616269 | ||
| Conformational changes of the flavivirus E glycoprotein | Q29618170 | ||
| Research on dengue during World War II | Q29619423 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. | Q50623862 | ||
| Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. | Q51066780 | ||
| West Nile virus. | Q51714865 | ||
| Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection | Q30398435 | ||
| Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues | Q30644992 | ||
| Epidemiology of dengue: past, present and future prospects | Q30664159 | ||
| Interactive electron-density map interpretation: from INTER to O. | Q31133209 | ||
| Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease | Q33255341 | ||
| A method for identification of HIV gp140 binding memory B cells in human blood | Q33394829 | ||
| Prospective study of leptospirosis transmission in an urban slum community: role of poor environment in repeated exposures to the Leptospira agent | Q33686158 | ||
| High-resolution description of antibody heavy-chain repertoires in humans | Q33988374 | ||
| Onset of immune senescence defined by unbiased pyrosequencing of human immunoglobulin mRNA repertoires | Q34505044 | ||
| Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants | Q34533041 | ||
| IgBLAST: an immunoglobulin variable domain sequence analysis tool | Q34720205 | ||
| Spatiotemporal Determinants of Urban Leptospirosis Transmission: Four-Year Prospective Cohort Study of Slum Residents in Brazil | Q35895082 | ||
| Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. | Q36132925 | ||
| Defective B cell tolerance checkpoints in systemic lupus erythematosus | Q36402748 | ||
| Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning | Q36459907 | ||
| Progress toward active or passive HIV-1 vaccination | Q37549777 | ||
| Broadly neutralizing antibodies against influenza viruses | Q37704975 | ||
| The human antibody response to dengue virus infection | Q37987124 | ||
| New insights into the immunopathology and control of dengue virus infection | Q38646923 | ||
| Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus | Q38782718 | ||
| Zika Virus: Immunity and Vaccine Development | Q38969772 | ||
| Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection | Q39008700 | ||
| Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice | Q40052932 | ||
| A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection | Q40344161 | ||
| Dengue Virus-Specific and Flavivirus Group Determinants Identified with Monoclonal Antibodies by Indirect Immunofluorescence | Q40843891 | ||
| The dengue group of viruses and its family relationships. | Q41064239 | ||
| In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire | Q41602128 | ||
| Rapid development of broadly influenza neutralizing antibodies through redundant mutations | Q41710834 | ||
| Prolonged Zika Virus Viremia during Pregnancy | Q43000496 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Brazil | Q155 |
| Zika virus | Q202864 | ||
| 2015–16 Zika virus epidemic | Q21686043 | ||
| antibody | Q79460 | ||
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 597-609.e11 | |
| P577 | publication date | 2017-05-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico | |
| P478 | volume | 169 |
| Q96174215 | A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations |
| Q58606057 | A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates |
| Q93101098 | A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy |
| Q54558504 | A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos. |
| Q90629672 | A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques |
| Q58611960 | A comparison of Zika and dengue outbreaks using national surveillance data in the Dominican Republic |
| Q97545865 | A complex between the Zika virion and the Fab of a broadly cross-reactive neutralizing monoclonal antibody revealed by cryo-EM and single particle analysis at 4.1 Å resolution |
| Q92759300 | A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits |
| Q84957921 | A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein |
| Q93065042 | A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection |
| Q41921198 | Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein |
| Q63246516 | An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus |
| Q92184359 | Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses |
| Q63246196 | Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus |
| Q92651078 | Antibody Complexes |
| Q59349915 | Antibody responses to Zika virus proteins in pregnant and non-pregnant macaques |
| Q84957976 | Association of past dengue fever epidemics with the risk of Zika microcephaly at the population level in Brazil |
| Q56341831 | Augmented Zika and dengue neutralizing antibodies are associated with Guillain-Barré syndrome |
| Q59349637 | Basics of memory B-cell responses: lessons from and for the real world |
| Q63246442 | Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen |
| Q83225458 | Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics |
| Q61053646 | CD4+ T cells promote humoral immunity and viral control during Zika virus infection |
| Q58744078 | CD4+T cells mediate protection against Zika associated severe disease in a mouse model of infection |
| Q52589484 | Can Zika virus antibodies cross-protect against dengue virus? - Authors' reply. |
| Q57464788 | Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus |
| Q58122069 | Complementary Mechanisms Potentially Involved in the Pathology of Zika Virus |
| Q60031649 | Comprehensive evaluation of differential serodiagnosis between Zika and dengue viral infection |
| Q64979406 | Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model. |
| Q95603877 | Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals |
| Q96576972 | Convergent antibody responses to SARS-CoV-2 in convalescent individuals |
| Q56341683 | Critical role of CD4 T cells and IFNγ signaling in antibody-mediated resistance to Zika virus infection |
| Q91711499 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade |
| Q61795493 | Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy |
| Q92184345 | Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes |
| Q47558158 | Development of Antibody Therapeutics against Flaviviruses |
| Q64247461 | Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure |
| Q47269331 | Development of envelope protein antigens to serologically differentiate Zika from dengue virus infection |
| Q63739941 | Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome |
| Q97649421 | Electron tomography visualization of HIV-1 fusion with target cells using inhibitors to trap the prehairpin intermediate |
| Q99552308 | Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro |
| Q104110902 | Enhanced SARS-CoV-2 neutralization by dimeric IgA |
| Q91621503 | Evolution of the innate and adaptive immune response in women with acute Zika virus infection |
| Q38158099 | Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction |
| Q92446647 | Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies |
| Q59245612 | Fast Tracks and Roadblocks for Zika Vaccines |
| Q90190740 | High specificity and sensitivity of Zika EDIII-based ELISA diagnosis highlighted by a large human reference panel |
| Q91675204 | Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein |
| Q58569620 | Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model |
| Q41929032 | Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection |
| Q63248442 | Human antibody response to Zika targets type-specific quaternary structure epitopes |
| Q97553503 | Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection |
| Q47558315 | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity |
| Q62485463 | Identification of Potential Lead Molecules for Zika Envelope Protein from In Silico Perspective |
| Q47551925 | Immune Response to Dengue and Zika |
| Q51336680 | Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development. |
| Q94948311 | Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation |
| Q63248468 | Immunogenicity and protection conferred by an optimized purified inactivated Zika vaccine in mice |
| Q62485447 | Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika |
| Q92024402 | Impacts of Zika emergence in Latin America on endemic dengue transmission |
| Q58758276 | Improved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans |
| Q63248475 | In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus |
| Q56000963 | Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein |
| Q90468197 | Influence of herd immunity in the cyclical nature of arboviruses |
| Q61448108 | Insights From Analysis of Human Antigen-Specific Memory B Cell Repertoires |
| Q98196926 | Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics |
| Q94523192 | Isolation of Monoclonal Antibodies from Zika Virus-Infected Patient Samples |
| Q66679510 | Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development |
| Q54241921 | Longitudinal Analysis of Antibody Cross-Neutralization Following Zika and Dengue Virus Infection in Asia and the Americas. |
| Q64124151 | Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection |
| Q92449663 | Longitudinal analysis of the antibody repertoire of a Zika virus-infected patient revealed dynamic changes in antibody response |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q38157121 | Monoclonal antibodies against Zika virus: Therapeutics and their implications for vaccine design |
| Q54265465 | Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. |
| Q47548101 | Passive immunotherapy of viral infections: 'super-antibodies' enter the fray |
| Q92343941 | Peptide-Based Subunit Vaccine Design of T- and B-Cells Multi-Epitopes against Zika Virus Using Immunoinformatics Approaches |
| Q90576774 | Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV |
| Q89519312 | Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor |
| Q101237271 | Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking |
| Q40043685 | Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design |
| Q99731978 | Protective and enhancing interactions among dengue viruses 1-4 and Zika virus |
| Q100763479 | Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2 |
| Q51336164 | Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. |
| Q92689707 | Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy |
| Q54215484 | Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope. |
| Q38158407 | Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure |
| Q91928841 | Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice |
| Q47681827 | Redefining priorities towards graded travel-related infectious disease research |
| Q92622870 | Risk of Zika microcephaly correlates with features of maternal antibodies |
| Q90148649 | Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies |
| Q90205634 | Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease |
| Q93162327 | Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody |
| Q61053963 | Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope |
| Q61053702 | The Decline of Dengue in the Americas in 2017: Discussion of Multiple Hypotheses |
| Q47558217 | The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. |
| Q58569778 | The immune response against flaviviruses |
| Q51336389 | The immunology of Zika Virus. |
| Q38156536 | Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus |
| Q48101193 | What Is a Host? Attributes of Individual Susceptibility |
| Q38157725 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine |
| Q92619848 | ZIKV Envelope Domain-Specific Antibodies: Production, Purification and Characterization |
| Q47130545 | Zika Virus: An Emerging Global Health Threat |
| Q60919470 | Zika Virus: Origins, Pathological Action, and Treatment Strategies |
| Q55645060 | Zika convalescent macaques display delayed induction of anmanestic cross-neutralizing antibody responses after dengue infection. |
| Q84957860 | Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and Fiji |
| Q97556920 | Zika virus RNA and IgM persistence in blood compartments and body fluids: a prospective observational study |
| Q38156674 | Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. |
| Q54558329 | Zika virus vaccines: immune response, current status, and future challenges. |
| Q44169814 | Zika virus: what we need to know? |
Search more.